Munehiro Kitada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Munehiro Kitada has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Daisuke Koya
Department of Diabetes and Endocrinology Kanazawa Medical University Kahoku District Ishikawa Japan
30 shared publications Yoshio Ogura
Department of Diabetology and Endocrinology Kanazawa Medical University Kahoku‐gun Japan
17 shared publicationsDaisuke Koya
Department of Diabetology and Endocrinology Kanazawa Medical University Uchinada Japan
14 shared publications- Keizo Kanasaki
Faculty of Medicine, Internal Medicine 1, Shimane University, Izumo, Japan
12 shared publications Itaru Monno
Department of Diabetology and Endocrinology Kanazawa Medical University Kahoku‐gun Japan
11 shared publicationsJing Xu
Kanazawa Medical University
8 shared publications
Latest Publications
- Open Access
- 18 May 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (8) , 1429-1438
Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study
Aim: To evaluate the effect of canagliflozin, a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor, on albuminuria and the decline of estimated glomerular filtration rate (eGFR) in participants with type 2 diabetes and microalbuminuria. Methods: The CANPIONE study is a multicentre, randomized, parallel‐group and open‐labelled study consisting of a unique 24‐week preintervention period, during which the rate of eGFR decline before intervention is estimated, followed by a 52‐week intervention and a 4‐week washout period. Participants with a geometric mean urinary albumin‐to‐creatinine ratio (UACR) of 50 and higher and less than 300 mg/g in two consecutive first‐morning voids at two different time points, and an eGFR of 45 ml/min/1.73m 2 or higher, are randomly assigned to receive canagliflozin 100 mg daily or to continue guideline‐recommended treatment, except for SGLT2 inhibitors. The first primary outcome is the change in UACR, and the second primary outcome is the change in eGFR slope. Results: A total of 258 participants were screened and 98 were randomized at 21 sites in Japan from August 2018 to May 2021. The mean baseline age was 61.4 years and 25.8% were female. The mean HbA1c was 7.9%, mean eGFR was 74.1 ml/min/1.73m 2 and median UACR was 104.2 mg/g. Conclusions: The CANPIONE study will determine whether the SGLT2 inhibitor canagliflozin can reduce albuminuria and slow eGFR decline in participants with type 2 diabetes and microalbuminuria.
- 18 May 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (8) , 1429-1438
Open AccessRationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study
Aim: To evaluate the effect of canagliflozin, a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor, on albuminuria and the decline of estimated glomerular filtration rate (eGFR) in participants with type 2 diabetes and microalbuminuria. Methods: The CANPIONE study is a multicentre, randomized, parallel‐group and open‐labelled study consisting of a unique 24‐week preintervention period, during which the rate of eGFR decline before intervention is estimated, followed by a 52‐week intervention and a 4‐week washout period. Participants with a geometric mean urinary albumin‐to‐creatinine ratio (UACR) of 50 and higher and less than 300 mg/g in two consecutive first‐morning voids at two different time points, and an eGFR of 45 ml/min/1.73m 2 or higher, are randomly assigned to receive canagliflozin 100 mg daily or to continue guideline‐recommended treatment, except for SGLT2 inhibitors. The first primary outcome is the change in UACR, and the second primary outcome is the change in eGFR slope. Results: A total of 258 participants were screened and 98 were randomized at 21 sites in Japan from August 2018 to May 2021. The mean baseline age was 61.4 years and 25.8% were female. The mean HbA1c was 7.9%, mean eGFR was 74.1 ml/min/1.73m 2 and median UACR was 104.2 mg/g. Conclusions: The CANPIONE study will determine whether the SGLT2 inhibitor canagliflozin can reduce albuminuria and slow eGFR decline in participants with type 2 diabetes and microalbuminuria.
- 29 April 2022
- Published by Springer Nature
- p. 175-188
Sirtuins and Metabolic Health
- Open Access
- 31 January 2022
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 13 (6) , 955-964
Adenosine/adenosine type 1 receptor signaling pathway did not play dominant roles on the influence of sodium–glucose cotransporter 2 inhibitor in the kidney of bovine serum albumin‐overloaded streptozotocin‐induced diabetic mice
Aims/Introduction A sodium glucose cotransporter 2 inhibitor (SGLT2i) has shown to display excellent renoprotective effects in DKD with macroalbuminuria/proteinuria. Regarding the renoprotective mechanism of SGLT2i, a sophisticated hypothesis was made by explaining the suppression of glomerular hypertension/hyperfiltration via the adenosine/adenosine type 1 receptor (A1R) signaling-mediated restoration of the tubulo-glomerular feedback mechanism; however, such A1R signaling is relevant for renoprotection by SGLT2i in DKD with proteinuria has not been elucidated. Materials and Methods STZ induced diabetic CD-1 mice were injected with bovine serum albumin (BSA) and treated with SGLT2i in the presence/absence of AIR inhibitor administration. Results We found that the influences of SGLT2i are essentially independent of the activation of A1R signaling in the kidney of BSA-overloaded streptozotocin-induced diabetic mice. BSA-overloaded diabetic mice displayed trend of kidney damage with higher glomerular filtration (GFR) and the significant induction of fibrogenic genes such as transforming growth factor (TGF)- β2 and collagen type III (COL3). SGLT2i TA-1887 suppressed diabetes-induced GFR in BSA-overloaded diabetic mice associated with the significant suppression of TGF-β2 and COL3; A1R-specific inhibitor 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) did not cancel the effects of TA-1887 on either GFR or associated gene levels. Both TA-1887 and DPCPX-treated BSA-overloaded diabetic mice displayed suppressed HbA1c levels associated with the increased food intake. When analyzing the association among histological evaluation, GFR and potential fibrogenic gene levels, each group of mice displayed distinct correlation patterns. Conclusions A1R signaling activation was not the dominant mechanism on the influence of SGLT2 inhibitor in the kidney of BSA-overloaded diabetic mice.
- 31 January 2022
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 13 (6) , 955-964
Open AccessAdenosine/adenosine type 1 receptor signaling pathway did not play dominant roles on the influence of sodium–glucose cotransporter 2 inhibitor in the kidney of bovine serum albumin‐overloaded streptozotocin‐induced diabetic mice
Aims/Introduction A sodium glucose cotransporter 2 inhibitor (SGLT2i) has shown to display excellent renoprotective effects in DKD with macroalbuminuria/proteinuria. Regarding the renoprotective mechanism of SGLT2i, a sophisticated hypothesis was made by explaining the suppression of glomerular hypertension/hyperfiltration via the adenosine/adenosine type 1 receptor (A1R) signaling-mediated restoration of the tubulo-glomerular feedback mechanism; however, such A1R signaling is relevant for renoprotection by SGLT2i in DKD with proteinuria has not been elucidated. Materials and Methods STZ induced diabetic CD-1 mice were injected with bovine serum albumin (BSA) and treated with SGLT2i in the presence/absence of AIR inhibitor administration. Results We found that the influences of SGLT2i are essentially independent of the activation of A1R signaling in the kidney of BSA-overloaded streptozotocin-induced diabetic mice. BSA-overloaded diabetic mice displayed trend of kidney damage with higher glomerular filtration (GFR) and the significant induction of fibrogenic genes such as transforming growth factor (TGF)- β2 and collagen type III (COL3). SGLT2i TA-1887 suppressed diabetes-induced GFR in BSA-overloaded diabetic mice associated with the significant suppression of TGF-β2 and COL3; A1R-specific inhibitor 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) did not cancel the effects of TA-1887 on either GFR or associated gene levels. Both TA-1887 and DPCPX-treated BSA-overloaded diabetic mice displayed suppressed HbA1c levels associated with the increased food intake. When analyzing the association among histological evaluation, GFR and potential fibrogenic gene levels, each group of mice displayed distinct correlation patterns. Conclusions A1R signaling activation was not the dominant mechanism on the influence of SGLT2 inhibitor in the kidney of BSA-overloaded diabetic mice.
- Open Access
- 27 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (1) , 137
Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches
Atherosclerosis-caused cardiovascular diseases (CVD) are the leading cause of mortality in type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter 2 (SGLT2) inhibitors are effective oral drugs for the treatment of T2DM patients. Multiple pre-clinical and clinical studies have indicated that SGLT2 inhibitors not only reduce blood glucose but also confer benefits with regard to body weight, insulin resistance, lipid profiles and blood pressure. Recently, some cardiovascular outcome trials have demonstrated the safety and cardiovascular benefits of SGLT2 inhibitors beyond glycemic control. The SGLT2 inhibitors empagliflozin, canagliflozin, dapagliflozin and ertugliflozin reduce the rates of major adverse cardiovascular events and of hospitalization for heart failure in T2DM patients regardless of CVD. The potential mechanisms of SGLT2 inhibitors on cardioprotection may be involved in improving the function of vascular endothelial cells, suppressing oxidative stress, inhibiting inflammation and regulating autophagy, which further protect from the progression of atherosclerosis. Here, we summarized the pre-clinical and clinical evidence of SGLT2 inhibitors on cardioprotection and discussed the potential molecular mechanisms of SGLT2 inhibitors in preventing the pathogenesis of atherosclerosis and CVD.
- 27 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (1) , 137
Open AccessEffects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches
Atherosclerosis-caused cardiovascular diseases (CVD) are the leading cause of mortality in type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter 2 (SGLT2) inhibitors are effective oral drugs for the treatment of T2DM patients. Multiple pre-clinical and clinical studies have indicated that SGLT2 inhibitors not only reduce blood glucose but also confer benefits with regard to body weight, insulin resistance, lipid profiles and blood pressure. Recently, some cardiovascular outcome trials have demonstrated the safety and cardiovascular benefits of SGLT2 inhibitors beyond glycemic control. The SGLT2 inhibitors empagliflozin, canagliflozin, dapagliflozin and ertugliflozin reduce the rates of major adverse cardiovascular events and of hospitalization for heart failure in T2DM patients regardless of CVD. The potential mechanisms of SGLT2 inhibitors on cardioprotection may be involved in improving the function of vascular endothelial cells, suppressing oxidative stress, inhibiting inflammation and regulating autophagy, which further protect from the progression of atherosclerosis. Here, we summarized the pre-clinical and clinical evidence of SGLT2 inhibitors on cardioprotection and discussed the potential molecular mechanisms of SGLT2 inhibitors in preventing the pathogenesis of atherosclerosis and CVD.
- Open Access
- 3 November 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (11) , 1754
Exercise Ameliorates Diabetic Kidney Disease in Type 2 Diabetic Fatty Rats
Lifestyle improvement, including through exercise, has been recognized as an important mode of therapy for the suppression of diabetic kidney disease (DKD). However, the detailed molecular mechanisms by which exercise exerts beneficial effects in the suppression of DKD have not yet been fully elucidated. In this study, we investigate the effects of treadmill exercise training (TET) for 8 weeks (13 m/min, 30 min/day, 5 days/week) on kidney injuries of type 2 diabetic male rats with obesity (Wistar fatty (fa/fa) rats: WFRs) at 36 weeks of age. TET significantly suppressed the levels of albuminuria and urinary liver-type fatty-acid-binding protein (L-FABP), tubulointerstitial fibrosis, inflammation, and oxidative stress in the kidneys of WFRs. In addition, TET mitigated excessive apoptosis and restored autophagy in the renal cortex, as well as suppressed the development of morphological abnormalities in the mitochondria of proximal tubular cells, which were also accompanied by the restoration of AMP-activated kinase (AMPK) activity and suppression of the mechanistic target of rapamycin complex 1 (mTORC1). In conclusion, TET ameliorates diabetes-induced kidney injury in type 2 diabetic fatty rats.
- 3 November 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (11) , 1754
Open AccessExercise Ameliorates Diabetic Kidney Disease in Type 2 Diabetic Fatty Rats
Lifestyle improvement, including through exercise, has been recognized as an important mode of therapy for the suppression of diabetic kidney disease (DKD). However, the detailed molecular mechanisms by which exercise exerts beneficial effects in the suppression of DKD have not yet been fully elucidated. In this study, we investigate the effects of treadmill exercise training (TET) for 8 weeks (13 m/min, 30 min/day, 5 days/week) on kidney injuries of type 2 diabetic male rats with obesity (Wistar fatty (fa/fa) rats: WFRs) at 36 weeks of age. TET significantly suppressed the levels of albuminuria and urinary liver-type fatty-acid-binding protein (L-FABP), tubulointerstitial fibrosis, inflammation, and oxidative stress in the kidneys of WFRs. In addition, TET mitigated excessive apoptosis and restored autophagy in the renal cortex, as well as suppressed the development of morphological abnormalities in the mitochondria of proximal tubular cells, which were also accompanied by the restoration of AMP-activated kinase (AMPK) activity and suppression of the mechanistic target of rapamycin complex 1 (mTORC1). In conclusion, TET ameliorates diabetes-induced kidney injury in type 2 diabetic fatty rats.
- Top Cited Papers
- 10 September 2021
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 17 (11) , 647-661
Autophagy in metabolic disease and ageing
Autophagy is an evolutionarily conserved, lysosome-dependent catabolic process whereby cytoplasmic components, including damaged organelles, protein aggregates and lipid droplets, are degraded and their components recycled. Autophagy has an essential role in maintaining cellular homeostasis in response to intracellular stress; however, the efficiency of autophagy declines with age and overnutrition can interfere with the autophagic process. Therefore, conditions such as sarcopenic obesity, insulin resistance and type 2 diabetes mellitus (T2DM) that are characterized by metabolic derangement and intracellular stresses (including oxidative stress, inflammation and endoplasmic reticulum stress) also involve the accumulation of damaged cellular components. These conditions are prevalent in ageing populations. For example, sarcopenia is an age-related loss of skeletal muscle mass and strength that is involved in the pathogenesis of both insulin resistance and T2DM, particularly in elderly people. Impairment of autophagy results in further aggravation of diabetes-related metabolic derangements in insulin target tissues, including the liver, skeletal muscle and adipose tissue, as well as in pancreatic β-cells. This Review summarizes the role of autophagy in the pathogenesis of metabolic diseases associated with or occurring in the context of ageing, including insulin resistance, T2DM and sarcopenic obesity, and describes its potential as a therapeutic target.
- 10 September 2021
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 17 (11) , 647-661
Top Cited PapersAutophagy in metabolic disease and ageing
Autophagy is an evolutionarily conserved, lysosome-dependent catabolic process whereby cytoplasmic components, including damaged organelles, protein aggregates and lipid droplets, are degraded and their components recycled. Autophagy has an essential role in maintaining cellular homeostasis in response to intracellular stress; however, the efficiency of autophagy declines with age and overnutrition can interfere with the autophagic process. Therefore, conditions such as sarcopenic obesity, insulin resistance and type 2 diabetes mellitus (T2DM) that are characterized by metabolic derangement and intracellular stresses (including oxidative stress, inflammation and endoplasmic reticulum stress) also involve the accumulation of damaged cellular components. These conditions are prevalent in ageing populations. For example, sarcopenia is an age-related loss of skeletal muscle mass and strength that is involved in the pathogenesis of both insulin resistance and T2DM, particularly in elderly people. Impairment of autophagy results in further aggravation of diabetes-related metabolic derangements in insulin target tissues, including the liver, skeletal muscle and adipose tissue, as well as in pancreatic β-cells. This Review summarizes the role of autophagy in the pathogenesis of metabolic diseases associated with or occurring in the context of ageing, including insulin resistance, T2DM and sarcopenic obesity, and describes its potential as a therapeutic target.
- Open Access
- 27 July 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (8) , 1198
Sirtuins and Renal Oxidative Stress
Renal failure is a major health problem that is increasing worldwide. To improve clinical outcomes, we need to understand the basic mechanisms of kidney disease. Aging is a risk factor for the development and progression of kidney disease. Cells develop an imbalance of oxidants and antioxidants as they age, resulting in oxidative stress and the development of kidney damage. Calorie restriction (CR) is recognized as a dietary approach that promotes longevity, reduces oxidative stress, and delays the onset of age-related diseases. Sirtuins, a type of nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylase, are considered to be anti-aging molecules, and CR induces their expression. The sirtuin family consists of seven enzymes (Sirt1–7) that are involved in processes and functions related to antioxidant and oxidative stress, such as DNA damage repair and metabolism through histone and protein deacetylation. In fact, a role for sirtuins in the regulation of antioxidants and redox substances has been suggested. Therefore, the activation of sirtuins in the kidney may represent a novel therapeutic strategy to enhancing resistance to many causative factors in kidney disease through the reduction of oxidative stress. In this review, we discuss the relationship between sirtuins and oxidative stress in renal disease.
- 27 July 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (8) , 1198
Open AccessSirtuins and Renal Oxidative Stress
Renal failure is a major health problem that is increasing worldwide. To improve clinical outcomes, we need to understand the basic mechanisms of kidney disease. Aging is a risk factor for the development and progression of kidney disease. Cells develop an imbalance of oxidants and antioxidants as they age, resulting in oxidative stress and the development of kidney damage. Calorie restriction (CR) is recognized as a dietary approach that promotes longevity, reduces oxidative stress, and delays the onset of age-related diseases. Sirtuins, a type of nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylase, are considered to be anti-aging molecules, and CR induces their expression. The sirtuin family consists of seven enzymes (Sirt1–7) that are involved in processes and functions related to antioxidant and oxidative stress, such as DNA damage repair and metabolism through histone and protein deacetylation. In fact, a role for sirtuins in the regulation of antioxidants and redox substances has been suggested. Therefore, the activation of sirtuins in the kidney may represent a novel therapeutic strategy to enhancing resistance to many causative factors in kidney disease through the reduction of oxidative stress. In this review, we discuss the relationship between sirtuins and oxidative stress in renal disease.
- Open Access
- 21 July 2021
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8
NAD+ Homeostasis in Diabetic Kidney Disease
The redox reaction and energy metabolism status in mitochondria is involved in the pathogenesis of metabolic related disorder in kidney including diabetic kidney disease (DKD). Nicotinamide adenine dinucleotide (NAD+) is a cofactor for redox reactions and energy metabolism in mitochondria. NAD+ can be synthesized from four precursors through three pathways. The accumulation of NAD+ may ameliorate oxidative stress, inflammation and improve mitochondrial biosynthesis via supplementation of precursors and intermediates of NAD+ and activation of sirtuins activity. Conversely, the depletion of NAD+ via NAD+ consuming enzymes including Poly (ADP-ribose) polymerases (PARPs), cADPR synthases may contribute to oxidative stress, inflammation, impaired mitochondrial biosynthesis, which leads to the pathogenesis of DKD. Therefore, homeostasis of NAD+ may be a potential target for the prevention and treatment of kidney diseases including DKD. In this review, we focus on the regulation of the metabolic balance of NAD+ on the pathogenesis of kidney diseases, especially DKD, highlight benefits of the potential interventions targeting NAD+-boosting in the treatment of these diseases.
- 21 July 2021
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8
Open AccessNAD+ Homeostasis in Diabetic Kidney Disease
The redox reaction and energy metabolism status in mitochondria is involved in the pathogenesis of metabolic related disorder in kidney including diabetic kidney disease (DKD). Nicotinamide adenine dinucleotide (NAD+) is a cofactor for redox reactions and energy metabolism in mitochondria. NAD+ can be synthesized from four precursors through three pathways. The accumulation of NAD+ may ameliorate oxidative stress, inflammation and improve mitochondrial biosynthesis via supplementation of precursors and intermediates of NAD+ and activation of sirtuins activity. Conversely, the depletion of NAD+ via NAD+ consuming enzymes including Poly (ADP-ribose) polymerases (PARPs), cADPR synthases may contribute to oxidative stress, inflammation, impaired mitochondrial biosynthesis, which leads to the pathogenesis of DKD. Therefore, homeostasis of NAD+ may be a potential target for the prevention and treatment of kidney diseases including DKD. In this review, we focus on the regulation of the metabolic balance of NAD+ on the pathogenesis of kidney diseases, especially DKD, highlight benefits of the potential interventions targeting NAD+-boosting in the treatment of these diseases.